JPRN-UMIN000031196
Completed
未知
Exploratory study evaluating efficacy and safety of hangeshashinto for treatment of Everolimus-associated stomatitis in patients with breast cancer. - Exploratory study evaluating efficacy and safety of hangeshashinto for treatment of Everolimus-associated stomatitis in patients with breast cancer.
Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital0 sites60 target enrollmentMarch 31, 2018
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients who have received radiotherapy or chemotherapy 2\) Known intolerance or hypersensitivity to everolimus or other rapamycin analogs 3\) Known impairment of gastrointestinal (GI) function or GI disease 4\) Diabetic patients HbA1c \>8%(without patients who have an anamnestic history) 5\) Patients who have any uncontrolled medical conditions such as \-Unstable angina pectoris, Symptomatic congestive heart failure of New York heart Association Class III or IV, myocardial infarction or any other clinically significant cardiac disease \<\= 6 months prior to start of Everolimus administration \-Active or severe infection \-Interstitial pneumonia, pulmonary or fibrosis accompanying dyspnea 6\) Patients who received live attenuated vaccines within 1 week of start of Everolimus administration and during the study 7\) Patients who have a history of another primary malignancy(Carcinoma in situ deemed to be cured by local treatment (lesions that are intraepithelial carcinoma or mucosal cancer) is not included) 8\) Brain metastasis that requires treatment for intracranial hypertension or emergency irradiation of the brain 9\) Pleural effusion, ascites, or pericardial effusion that requires emergency treatment 10\) Patients who have not had resolution of prior anti\-cancer therapy to NCI CTCAE version 4\.0 Grade 1 11\) Difficulty to participate in this study due to mental illness or psychiatric symptoms 12\) Patients who took prohibited medicines or the investigational drug within 4 weeks before enrollment 13\) Patients who participated in another study within 4 weeks before enrollment 14\) Patients who are pregnancy, possibly pregnancy, considering pregnancy or lactating 15\) Patients who are allergic to Kampo medicine 16\) Patients who are determined not applicable for the study by the physicians
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Exploratory study evaluating efficacy and safety of daikenchuto for the treatment of the postoperative abdominal pain or bloating in patients undergoing hepatectomy.Abdominal pain or bloating after hepatectomyJPRN-UMIN000028950agasaki University40
Recruiting
Phase 2
OLZOINV studyOpioid-induced nausea and vomitingJPRN-jRCTs031220008Satomi Eriko35
Recruiting
Phase 2
Photodynamic diagnosis by LED endoscopy systemAlimentary canal tumorJPRN-jRCTs061200034Isomoto Hajime60
Recruiting
Phase 1
Exploratory trial to assess the efficacy and safety of Psilocybin-Assisted Psychotherapy (PAP) involving family-members compared to standard PAP, in adults with treatment-resistant major depressive disorder. (TRMDD).Treatment-resistant major depressive disorder (TRMDD).Mental Health - DepressionACTRN12623000618651Reset Mind Science60
Recruiting
Not Applicable
Exploratory study evaluating efficacy, safety and mechanism of Daikenchuto on abdominal pain or bloating accompanied by Crohn disease.Subjects with quiescent Crohn disease having abdominal pain or bloatingJPRN-UMIN000012635Kurume university30